baber/WOPTO huggingface dataset:
Patent NZ-550447-A (NZ)
Title: Hexafluoro-indolyl derivatives as liver-x-receptor modulators
Inventor: DEHMLOW HENRIETTA
IPC: C07D417/06
Filed: 2005-04-26
Abstract: Disclosed are 2-(indol-5-yl)-1,1,1,3,3,3-hexafluoro-propan-2-ol derivatives as represented by formula (I), wherein A is an optionally substituted aryl or heterocyclic ring, and the other substituents are as defined herein. Also disclosed is the use of a therapeutically active substance as defined above for the preparation of medicaments for the prophylaxis and therapy of diseases which are modulated by LXR alpha and/or LXR beta agonists (diseases such as increased lipid levels, increased cholesterol levels, low HDL-cholesterol, high LDL-cholesterol, atherosclerotic diseases, diabetes, non-insulin dependent diabetes mellitus, metabolic syndrome, dyslipidemia, sepsis, inflammatory diseases, skin diseases, colitis, pancreatitis, cholestasis of the liver. fibrosis of the liver, macular degeneration or Alzheimer's disease).
Patent NZ-562347-A (NZ)
Title: Biogenic fuel gas generation in geologic hydrocarbon deposits
Inventor: PFEIFFER ROBERT S
IPC: E21B47/10
Filed: 2007-01-29
Abstract: Disclosed is a method to stimulate biogenic production of a combustible gas, the method comprising: measuring a salinity level of formation water in a geologic formation; forming an opening in the formation to provide access to a consortium of microorganisms; extracting a portion of formation water from the opening in the formation, and removing at least some of the salt from the formation water to produce treated water; injecting the treated water into the formation; and measuring a change in the rate of production of the combustible gas in the formation.
Patent NZ-562436-A (NZ)
Title: Toll-like receptor 14 (TLR14) and use thereof
Inventor: OAENEILL LUKE ANTHONY JOHN
IPC: C07K14/705
Filed: 2006-04-18
Abstract: Provided is the use of a polypeptide comprising a fragment or variant of the protein TLR14 (KIAA0644) in the manufacture of a medicament for the treatment of an immune or inflammatory disorder, wherein the fragment comprises at least 12 contiguous amino acids, and the variant comprises an amino acid sequence that is at least 70% identical to the amino acid sequence of the specified sequences. Further provided are methods of identifying compounds with Toll-like receptor activity using the polypeptides or genes encoding the polypeptides.
Patent NZ-563459-A (NZ)
Title: A method of marking a composition for use in oral administration
Inventor: MOMOI KAZUHISA
IPC: A61K9/44
Filed: 2006-05-24
Abstract: Disclosed is a method for manufacturing a marked composition for use in oral administration, comprising the steps of: (a) dispersing a change in colour-inducing oxide (such as titanium dioxide, yellow ferric oxide or red ferric oxide) in the composition for use in oral administration; and (b) scanning a surface of the composition for use in oral administration with a laser beam at wavelengths of from 200 nm to 1100 nm and with from 0.1 W to 50 W average power to make a particle of the change in colour-inducing oxide agglomerate so as to become discoloured. Also disclosed is a marked oral composition manufactured by the above method, wherein the composition for use in oral administration is a tablet or a capsule.
Patent NZ-569102-A (NZ)
Title: Novel thiophene derivatives
Inventor: BOLLI MARTIN
IPC: A61K31/381
Filed: 2006-11-22
Abstract: The disclosure relates to thiophene derivatives of formula (I), their preparation and their use as pharmaceutically active compounds, wherein the variables are as defined in the specification. Said compounds particularly act as immunosuppressive agents.
Patent NZ-569555-A (NZ)
Title: Compositions and methods of use for antibodies of Dickkopf-1 and/or -4
Inventor: SHULOK JANINE
IPC: A61P35/04
Filed: 2007-01-12
Abstract: Provided is a composition comprising an isolated antibody or functional fragment thereof, comprising an antigen-binding region that specifically binds an epitope in a human DKK1 polypeptide, wherein the isolated antibody or functional fragment thereof comprises a heavy chain and light chain comprising six CDRs. The composition can be used to treat various cancers and myelomas and diabetes, among other diseases.
Patent NZ-571162-A (NZ)
Title: Liquified petroleum gas fracturing system including the use of inert gas to purge components
Inventor: LOREE DWIGHT N
IPC: C09K8/64
Filed: 2007-03-02
Abstract: A fracturing system for a well, includes a frac pressure pump 10 through which a stream of LPG 16, propane, butane, or a mixture of propane and butane, is injected into the well 14 at a high frac pressure. Proppant 22 (various types of sand) is supplied into the LPG stream, and carried by the LPG mix into the formation. Inert gas 28 such as nitrogen is used for purging system components of LPG prior to commencement of and during the frac procedure, and to help protect against risk of explosion. Nitrogen may also be added to the LPG mix during a frac of shale gas or coal gas formations. Once fractures are created in the formation by pressurisation of the frac fluid in the well, the pressure is released from the well to allow the frac fluid to vaporise and return to the surface. A controller 32 is connected to control the operation of the frac fluid source, the frac pressure pump, the inert gas source, and the proppant supply.
Patent NZ-571746-A (NZ)
Title: Process for producing high-purity prasugrel and acid addition salt thereof
Inventor: INOUE TERUHIKO
IPC: C07D495/04
Filed: 2007-04-06
Abstract: Disclosed is a method for producing prasugrel hydrochloride represented by the formula (Ia), comprising: preparing free prasugrel represented by the formula containing 5-(alpha-cyclopropylcarbonyl-2-fluorobenzyl)-2-oxo-2,4,5,6,7,7ahexahydrothieno[3,2-c ]pyridine from a 2-silyloxy-5-(alpha-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno [3,2-c]pyridine; dissolving the free prasugrel in an inert solvent; and adding hydrochloric acid to the solution for reaction.
Patent NZ-578881-A (NZ)
Title: Estimating the airflow through a PAP device from a motor's speed and adjusting the motor's control current accordingly
Inventor: FARRUGIA STEVEN PAUL
IPC: A61M16/00
Filed: 2005-11-02
Abstract: A method for determining airflow through a Positive Airway Pressure (PAP) device by a processor-controlled PAP device. This is done by measuring the actual speed of a blower motor (16), determining a desired motor current required to maintain a desired motor speed and using both the actual motor speed and desired motor current in a polynomial flow-estimation algorithm to determine flow through the PAP device (12). An apparatus for performing this is also disclosed.
Patent NZ-585627-A (NZ)
Title: Bivalent, bispecific antibodies
Inventor: KLEIN CHRISTIAN
IPC: C07K16/28
Filed: 2008-12-16
Abstract: Disclosed is a bivalent, bispecific antibody, comprising: a) the light chain and heavy chain of an antibody specifically binding to a first antigen; and b) the light chain and heavy chain of an antibody specifically binding to a second antigen, wherein the variable domains VL and VH are replaced by each other. Also disclosed is a method for the preparation of the antibody.
Patent NZ-586675-A (NZ)
Title: Pharmaceutically acceptable salts of 2-{ 4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide
Inventor: FOLEY JENNIFER R
IPC: C07D401/10
Filed: 2009-01-08
Abstract: Disclosed are compounds selected from: (3S)-3-{ 4-[7-(Aminocarbonyl)-2H-indazol-2-yl]phenyl} piperidinium 4-methylbenzenesulfonate; (3S)-3-{ 4-[7-(Aminocarbonyl)-2H-indazol-2-yl]phenyl} piperidinium sulfate; (3S)-3-{ 4-[7-(Aminocarbonyl)-2H-indazol-2-yl]phenyl} piperidinium benzenesulfate; (3S)-3-{ 4-[7-(Aminocarbonyl)-2H-indazol-2-yl]phenyl} piperidinium fumarate; (3S)-3-{ 4-[7-(Aminocarbonyl)-2H-indazol-2-yl]phenyl} piperidinium succinate; (3S)-3-{ 4-[7-(Aminocarbonyl)-2H-indazol-2-yl]phenyl} piperidinium 4-methylbenzenesulfonate monohydrate. The compounds are used to treat cancer, inflammatory diseases, reperfusion injuries, ischemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes, neurodegenerative diseases, retroviral infection, retinal damage or skin senescence and UV induced skin damage.
Patent NZ-587209-A (NZ)
Title: Process and plant for treating a water stream
Inventor: HODGKINSON ANDREW
IPC: B01D61/00
Filed: 2008-12-22
Abstract: 587209 A process for treating a water stream containing dissolved organic carbon and dissolved salts including sulfate, comprising subjecting the water stream to a reverse osmosis treatment step 20 to produce a treated water stream where prior to treatment of water in the reverse osmosis step, the water stream is treated in a plurality of pre-treatment steps to substantially reduce the amount of dissolved organic carbon and sulfate directed in water to the reverse osmosis step, the water stream pre-treatment steps comprising i) An anerobic process AR1, AR2 reducing sulfate contained in the water stream to sulfide while producing biogas, ii) Aeration of water directed from the anaerobic process, and iii) A membrane treatment step MBR involving nanofiltration of water pretreated by step (ii).
Patent NZ-594343-A (NZ)
Title: Novel anti-alpha5beta1 antibodies and uses thereof
Inventor: LIANG WEI-CHING
IPC: A61K39/395
Filed: 2010-03-23
Abstract: NZ 594343 Disclosed is an anti-alpha5beta1 antibody comprising a VL domain comprising a CDR-L1 comprising TL-S/T S/P/T-Q/N-H-F/S-T/I-YK/T-I-G/D/S (SEQ ID NO:15); a CDR-L2 comprising L/I-N/T-S-D/H/S-G/S-S/L/T-H/YN/K/Q/I-K/T-G/A-D/S/V (SEQ ID NO:16); a CDR-L3 comprising G/A-S/A/Y-S/Y-YS/A/Y-S/Y/T-GY-V/I (SEQ ID NO:17); and a VH domain comprising a CDR-H1 comprising GFTFS-N/A-RW-I/V-Y (SEQ ID NO:18); a CDR-H2 comprising GIKTKP-N/A/T-I/R-YAT-E/Q-YADSVKG (SEQ ID NO:19); and a CDR-H3 comprising L/V-TG-M/K-R/K-YFDY (SEQ ID NO:20). Also disclosed is the use of said antibody in the manufacture of a medicament for treating an individual having a disease or disorder involving abnormal angiogenesis and/or vascular permeability or leakage.
Patent NZ-602166-A (NZ)
Title: Antibodies to il-6 and use thereof
Inventor: GARCIA-MARTINEZ LEON
IPC: A61K39/00
Filed: 2009-11-24
Abstract: Patent No. 602166 Disclosed is a composition formulated to treat or detect a disease associated with elevated IL-6, containing an anti-IL-6 antibody or antibody fragment, wherein the antibody or fragment comprises the VL polypeptide of AIQMTQSPSSLSASVGDRVTITCQASQSINNELSWYQQKPGKAPKLLIYRASTLASGVPSRFSGSGSGTDFTLTISSLQPDDFATYYCQQGYSLRNIDNAFGGGTKVEIKR and the VH polypeptide of EVQLVESGGGLVQPGGSLRLSCAASGFSLSNYYVTWVRQAPGKGLEWVGIIYGSDETAYATWAIGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDDSSDWDAKFNLWGQGTLVTVSS or EVQLVESGGGLVQPGGSLRLSCAASGFSLSNYYVTWVRQAPGKGLEWVGIIYGSDETAYATSAIGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDDSSDWDAKFNLWGQGTLVTVSS, with the proviso that said composition does not comprise a therapeutic or diagnostic agent other than said anti-IL-6 antibody or antibody fragment.
Patent NZ-607796-A (NZ)
Title: Bioactive compositions comprising ficus serum fraction and methods to reduce the appearance of skin hyperpigmentation
Inventor: KOGANOV MICHAEL
IPC: A61K8/97
Filed: 2011-09-09
Abstract: Disclosed is a composition derived from fresh Ficus leaf juice, wherein said composition is Ficus Serum Fraction. Further disclosed is a process for making a Ficus cell serum fraction composition, said process comprising: a. separating ficus cell juice from clean, fresh, un-wilted ficus leaves to obtain fresh ficus cell juice, wherein no exogenous liquid is added prior or during said separating; b. filtering said fresh ficus cell juice to obtain fiber-free cell juice; and c. fractionating said fiber-free cell juice to obtain Ficus Serum Fraction, wherein said fractionating comprises: (1) removing chlorophyll from said fiber-free cell juice to obtain Supernatant I; (2) removing pigments and proteins from Supernatant I to form Ficus Serum Fraction.
Patent NZ-618697-A (NZ)
Title: Autologous surgical bone collection and filtration
Inventor: HENSLER ROBERT SEAN
IPC: A61M1/34
Filed: 2012-05-04
Abstract: A kit for collecting and thereafter filtering bone from blood. The kit comprises a collection trap (302), that is a container with a mouth. The container has a first and a second cover (102, 202); wherein the first and second cover (102, 202) are interchangeably attachable to the collection trap (302) in a sealing engagement covering the mouth of the container. The first cover (102) comprises a suction port and an intake port, and is configured to be used when attached to the container for collecting blood and bone suctioned into the container through the intake port as a result of application of suction via the suction port. The second cover (202) is configured to be interchanged with the first cover (102) following the collection of blood and bone in the container comprises a suction port. The kit also includes a plunger (216) with a press head, and a vent configured to permit air to enter into the container as a result of the application of suction via the suction port of the second cover (202), the air entering into the container through an opening in the second cover located proximate the mouth of the container and in spaced relation to the press head.
Patent NZ-620642-A (NZ)
Title: A mower
Inventor: NICHOLAS JOHN BARNES
IPC: A01D75/30
Filed: 2013-02-11
Abstract: A mower that is able to follow contours in the ground is disclosed. The mower is formed so that it can be secured to, and moved along the ground, by a motor vehicle (7) such as an agricultural tractor. Ground engaging means (3) run along the ground so the blade(s) (2) can mow vegetation at about ground level. The main structure (1) of the mower, ground engaging means (3) and blade (2) are able to pivot with respect to the vehicle mounting structure (5) via connection means (4, 8). This provides a measure of protection against the blade(s) hitting the ground in the event the mower is moved by the vehicle on uneven terrain. The connection means may comprise pins (8) running in slots (4) which is particularly suited for a mower which is mounted at the front of the vehicle.
Patent NZ-627473-A (NZ)
Title: Aryloxyacetamide compound and pesticide
Inventor: FURUKAWA HIRONORI
IPC: C07D417/12
Filed: 2013-02-12
Abstract: Disclosed are aryloxyacetamide compounds represented by a formula such as formula (I) or a salt thereof, and a pesticide containing the compound or salt thereof as an active ingredient.
Patent NZ-701889-A (NZ)
Title: Ophthalmic lens
Inventor: DE AYGUAVIVES FRANCISCO
IPC: G02C7/10
Filed: 2013-05-16
Abstract: The present invention relates to an ophthalmic lens, one or both main faces of which comprises an optical filter intended to reduce the blue light-induced phototoxic effects on the retina of a spectacle wearer. It is an object of the present invention to provide an ophthalmic lens comprising a reflection filter, which would take the whole light irradiation into account, which originates from the surrounding area, and reduce the blue light amount received by the eye within the wavelength range of from 420 nm to 450 nm. It is another object of the present invention to provide an ophthalmic lens comprising such a reflection filter, which enables an outstanding transmission within the wavelength range of from 465 nm to 495 nm. Said filter provides the face comprising it with the following properties: an average blue reflectance factor within a wavelength range of from 420 nm to 450 nm, which is higher than or equal to 5%, for an angle of incidence ranging from 0° to 15°; a spectral reflectivity curve for an angle of incidence ranging from 0° to 15°, which presents a maximum reflectivity at a wavelength of less than 435 nm, and a full width at half maximum higher than or equal to 80 nm; and for an angle of incidence θ ranging from 0° to 15° and for an angle of incidence θ’ ranging from 30° to 45°, a parameter Δ(θ,θ’) defined by the relation Δ(θ,θ’) = 1 - [ Rθ’(435 nm) / Rθ(435 nm) ] so that this parameter Δ(θ,θ’) is higher than or equal to 0.6, where Rθ(435 nm) is the reflectivity value of the main face comprising said filter at a wavelength of 435 nm for the angle of incidence θ, and Rθ’(435 nm) is the reflectivity value of the main face comprising said filter at a wavelength of 435 nm for the angle of incidence θ’.
Patent NZ-703633-A (NZ)
Title: Solid agave syrup compositions
Inventor: ROWE JOHN LAWRENCE
IPC: A23L27/10
Filed: 2013-07-11
Abstract: The present invention relates to a agave syrup product having a low water content. The agave syrup product retains the physical and palatable properties of untreated agave syrup while having a prolonged shelf-life. It can be advantageously used to sweeten beverages (such as hot beverages) and in the manufacture of pharmaceutical compositions (such as throat lozenges) and/or confectionary.
Patent NZ-705814-A (NZ)
Title: Method for the removal and control of arthropod infestation in interior dwellings
Inventor: DEEB THOMAS M
IPC: A01P7/04
Filed: 2013-09-13
Abstract: While many individual methods to combat the problem of controlling bed bug infestations in interior dwellings have been tried before, the previously disclosed methods or systems have not effectively solved the ongoing problem. The present invention aims to solve the problem by providing an alternative method for use in the control of bed bugs infestation in an interior dwelling space. The method comprises cleaning and physically removing bed bugs in all life forms, including adults, larvae and eggs, from surfaces and objects within the interior dwelling space, using a high efficiency water extraction device. Water that is heated to a temperature sufficient to kill or immobilize the bed bug adults, larvae and eggs is utilized and to which is added a cleaning agent comprising from about 0.001 to about 5.0% of a first surfactant selected from the group consisting of a fluorochemical surfactant and a siloxane surfactant. The method further comprises applying an arthropod control composition to surfaces and objects within the interior dwelling space. The composition comprises a non-carbamate arthropod control agent and from about 0.001 to about 5.0% of a second surfactant selected from the group consisting of a fluorochemical surfactant and a siloxane surfactant.
Patent NZ-711329-A (NZ)
Title: A process for preparation of (2s, 5r)- sulfuric acid mono-{ [(4-aminopiperidin-4-yl) carbonyl]-7-oxo-1,6-diaza-bicyclo[3.2.1]-oct-6-yl} ester
Inventor: PATEL MAHESH VITHALBHAI
IPC: C07D471/08
Filed: 2013-10-12
Abstract: A process for preparation of (2S, 5R)- Sulfuric acid mono-{ [(4- aminopiperidin-4-yl) carbonyl]-7-oxo-1,6-diaza-bicyclo[3.2.1]-oct-6-yl} ester is disclosed which comprises reacting a compound of Formula (II) with a compound of Formula (III) to obtain a compound of Formula (IV).
Patent NZ-712289-A (NZ)
Title: Crystalline form of r)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
Inventor: REICHENBACHER KATHARINA
IPC: C07F9/12
Filed: 2010-02-03
Abstract: Disclosed is a pharmaceutical composition that is a lyophilisate of a sodium salt formed in situ from a reaction mixture including (i) sodium hydroxide and (ii) crystalline particles including 96% or more by weight of (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one (tedizolid) dihydrogen phosphate; and at least one pharmaceutically acceptable carrier, excipient or diluent. Also disclosed is a lyophilised powder for injection made by a process comprising mixing tedizolid dihydrogen phosphate with a sodium hydroxide solution to form a disodium salt of said compound and then lyophilizing the resulting solution.
Patent NZ-712949-A (NZ)
Title: Imidazo-triazine derivatives as pde10 inhibitors
Inventor: KORMOS BETHANY LYN
IPC: C07D519/00
Filed: 2014-04-23
Abstract: The present invention is directed to a new class of triazine derivatives as described by formula (I) below in which A, X, R1, R2, R3, and R4 are as defined herein and to the use of the compounds as PDE10 inhibitors.
Patent NZ-717728-A (NZ)
Title: Stable formulations of a hyaluronan-degrading enzyme
Inventor: VAUGHN DANIEL EDWARD
IPC: A61P5/50
Filed: 2012-06-15
Abstract: Discloses a composition, comprising: a hyaluronidase; and lysyl lysine (Lys-Lys) in an amount to render the hyaluronidase stable.
Patent NZ-719350-A (NZ)
Title: Injectable parasiticidal formulations of levamisole and macrocyclic lactones
Inventor: RAZZAK MAJID
IPC: A61P33/10
Filed: 2011-05-12
Abstract: The disclosure relates to a pharmaceutically or veterinarily acceptable micellar solution formulation adapted to be injected into an animal, which formulation comprises; (a) an effective amount of a levamisole; (b) an effective amount of at least one macrocyclic lactone; (c) a pharmaceutically acceptable system of solvents and surfactants, wherein the system provides for acceptable storage stability for both the levamisole and the macrocyclic lactone and wherein the system provides for a viscosity which is suitable for injection; wherein the surfactants comprise at least polyoxyethylenated esters of sorbitan, a polyethylene glycol stearate, or both; and wherein the solvents comprise at least a water miscible organic solvent selected from glycerol formal (GF), propylene glycol, dimethyl acetamide (DMA), or combinations thereof, but not n-methyl pyrrolidone (NMP); wherein the levamisole is levamisole HCl; wherein the macrocyclic lactone is eprinomectin or ivermectin; wherein the formulation comprises water for injection; wherein the water for injection is provided in a quantity sufficient to bring the formulation to a suitable injection volume; and with the proviso that when the macrocyclic lactone is ivermectin, the levamisole HCl is present in an amount of at least about 15% (w/v).
Patent NZ-746944-A (NZ)
Title: Use of a cd6 binding partner and method based thereon
Inventor: MANIAN BALA S
IPC: A61K39/395
Filed: 2014-07-23
Abstract: The present invention relates to use of an Itolizumab antibody for the treatment of an allograft rejection or graft-versus host disease in a subject, wherein the subject has an increased number of T helper 17 (Thl7) cells when compared to a healthy subject, wherein the Itolizumab antibody is a humanized antibody specifically binding to D1 of CD6 and wherein the Itolizumab antibody reduces expression and activation of CD4+ T cells and Thl7 cytokines, wherein the Th17 cytokine is one or more selected from the group consisting of TNF-alpha, IL-17, and IL-17A.
Patent NZ-748326-A (NZ)
Title: Manufacturing of semi-plastic pharmaceutical dosage units
Inventor: KLUGER DOMINIQUE
IPC: B29C41/04
Filed: 2013-11-19
Abstract: A process for the manufacture of semi-plastic soft chewable veterinary pharmaceutical unit doses containing 4-[5-[3-chloro-5-(trifluoromethyl)phenyl]-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-N-[2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl]-1-naphthalenecarboxamide (afoxolaner) using a rotary moulding machine to achieve uniform shape and active ingredient content, and the semi-plastic soft chewable veterinary pharmaceutical dosage units obtained by this process.
Patent NZ-751185-A (NZ)
Title: New use of triazolo(4,5-d)pyrimidine derivatives for prevention and treatment of bacterial infection
Inventor: OURY CÉCILE
IPC: A61K31/519
Filed: 2017-07-25
Abstract: Triazolo(4,5-d)pyrimidine derivatives for use in treatment or prevention of bacterial infection in a host mammal in need of such treatment or use as inhibitor of biofilm formation on a surface of biomaterial or medical device, particularly of cardiovascular device such as prosthetic heart valve or pacemakers.